– Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx –
– This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care –
– Results will be submitted to global health authorities including the U.S. Food and Drug Administration –
https://finance.yahoo.com/news/genentech-lunsumio-polivy-combination-significantly-154500744.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.